Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - therapeuticarea+%3e+immunology
197
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Fluorinated MU-Opioid Receptor Agonists
Summary: Investigators at the National Institute on Drug Abuse seek co-development partners and/or licensees for collection of mu opioid receptor (MOR) agonists as alternatives for existing compounds. Description of Technology: Although existing opioids are excellent analgesics and useful as positron emission tomography (PET) radiotracers, they come...
Published: 12/20/2024
|
Inventor(s):
Michael Michaelides
,
Juan Gomez
,
Kenner Rice
,
Agnieszka Sulima
,
Michael Baumann
Keywords(s):
Category(s):
Application
,
Application > Therapeutics
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Immunology
,
TherapeuticArea > Neurology
,
TherapeuticArea > Radiology
,
Collaboration Sought > Licensing
A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics
BSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome...
Published: 12/10/2024
|
Inventor(s):
Ursula Buchholz
Keywords(s):
Category(s):
Application > Therapeutics
,
Application > Vaccines
,
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
ResearchProducts > Research Equipment
,
TherapeuticArea > Immunology
,
TherapeuticArea > Infectious Disease
Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense
The technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent...
Published: 12/10/2024
|
Inventor(s):
Zhao Chun Chen
,
Robert Purcell
,
Mahtab Moayeri
,
Stephen Leppla
Keywords(s):
Category(s):
Application > Therapeutics
,
Application > Vaccines
,
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
ResearchProducts > Antibodies
,
TherapeuticArea > Immunology
,
TherapeuticArea > Infectious Disease
Transgenic Mouse Models for Studying HLA-B57:01 and HLA-B15:02 Linked Immune Responses and Hypersensitivity Reactions
Transgenic mouse models expressing human HLA-B57:01 and HLA-B15:02 molecules have emerged as invaluable tools for unraveling the intricacies of immune responses and hypersensitivity reactions. The major histocompatibility complex (MHC) encoded proteins play a pivotal role in the immune system by presenting peptide fragments to T lymphocytes, and HLA-B57:01...
Published: 12/10/2024
|
Inventor(s):
David Margulies
,
Kannan Natarajan
,
Mulualem Tilahun
,
Michael Norcross
,
Lisa Boyd
Keywords(s):
Category(s):
Application > Research Materials
,
Collaboration Sought > Collaboration
,
ResearchProducts > Animal Models
,
ResearchProducts > Research Equipment
,
TherapeuticArea > Immunology
Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection
LAD2 and LADR cell lines are invaluable tools in mast cell research, offering insights into mastocytosis and immune responses. Derived from CD34+ cells, LAD2 cells have been extensively used for over 18 years, while LADR cells, a newer variant, exhibit enhanced characteristics such as larger size, increased granulation, and faster doubling time. Both...
Published: 12/10/2024
|
Inventor(s):
Arnold Kirshenbaum
,
Dean Metcalfe
Keywords(s):
Category(s):
Application > Research Materials
,
Collaboration Sought > Collaboration
,
ResearchProducts > Human Cell Lines
,
TherapeuticArea > Immunology
,
TherapeuticArea > Infectious Disease
Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors
Summary: The National Cancer Institute (NCI) seeks research co-development partners and licensees for a panel of five fully human antibodies against CD276 for the treatment of solid tumors. The collection also includes human CARs incorporating the antibodies for immunotherapeutic use. Description of Technology: Chimeric antigen receptor (CAR)-T...
Published: 12/20/2024
|
Inventor(s):
Brad St. Croix
,
Pradip Bajgain
,
Yang Feng
Keywords(s):
Category(s):
Application > Therapeutics
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Oncology
,
TherapeuticArea > Immunology
,
Collaboration Sought > Licensing
Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies
Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways. Description of Technology: Immunotherapy is...
Published: 12/9/2024
|
Inventor(s):
Scott Norberg
,
Andrew Sinkoe
,
Xiaolin Wu
,
James Gulley
Keywords(s):
Category(s):
Application > Diagnostics
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Oncology
,
TherapeuticArea > Immunology
Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for three small molecules that target hRpn13, an overexpressed protein in certain cancers. Description of Technology: Over 35,000 new cases of multiple myeloma are diagnosed each year in the US. Standard of care and experimental therapies include...
Published: 12/20/2024
|
Inventor(s):
Kylie Walters
,
Xiuxiu Lu
Keywords(s):
Category(s):
Application > Therapeutics
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Oncology
,
TherapeuticArea > Immunology
,
Collaboration Sought > Licensing
Tixocortol for the Prevention or Treatment of SARS-CoV-2 and Other Coronaviruses
Summary: The National Cancer Institute (NCI) seeks collaborators and/or licensees for co-development and commercialization of an inhibitor of coronavirus main protease. Description of Technology: The recent COVID-19 pandemic led to millions of deaths worldwide – presenting an urgent need to develop vaccines and therapeutics against SARS-CoV-2...
Published: 12/20/2024
|
Inventor(s):
David Davis
,
Robert Yarchoan
,
Brett Eaton
,
Richard Gussio
,
Brian Peyser
,
Tam Nguyen
,
Ashwin Nair
,
Yana Astter
Keywords(s):
Category(s):
Application > Therapeutics
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Infectious Disease
,
TherapeuticArea > Immunology
,
Collaboration Sought > Licensing
Immunotherapy Delivery System to Improve Organ Transplantation Outcomes
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway. Description of Technology: Value Proposition • Novel Therapy: Hydro(LNp), is a new therapeutic application to improve outcomes for organ...
Published: 12/6/2024
|
Inventor(s):
Giorgio Raimondi
,
Joel Schneider
,
Julia Patrone
,
Alexander Komin
,
Monessha Nambiar
,
Xiomara Calderon-Colon
,
Olivia Tiburzi
Keywords(s):
Category(s):
Application > Therapeutics
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Immunology
,
TherapeuticArea > Cardiology
,
TherapeuticArea > Nephrology
1
2
3
4
5
6
7
8
9
10
...